Circular Genomics Enhances Scientific Advisory Board with Alzheimer's Specialist Appointment

Circular Genomics Strengthens Its Scientific Advisory Board

Appointment of Phyllis Barkman Ferrell, MBA, DrPH

Circular Genomics, a frontrunner in the development of circular RNA (circRNA) biomarkers used in precision neurology and psychiatry, has recently revealed a significant addition to its Scientific Advisory Board (SAB). The esteemed Dr. Phyllis Barkman Ferrell, with her extensive experience in neurological conditions, primarily focusing on Alzheimer's disease, is set to provide invaluable insights and expertise to enhance the company's mission in diagnosing and treating psychiatric and neurological disorders.

This landmark appointment reflects Circular Genomics’ commitment to advancing the understanding and treatment of serious conditions such as dementia and Alzheimer’s disease. The company is renowned for its innovative research, striving to establish circRNAs as reliable blood biomarkers for neurological disorders. The inclusion of Dr. Ferrell in the SAB aims to further innovate solutions, enhancing early diagnosis and treatment accuracy for Alzheimer's disease, which affects millions globally.

Dr. Ferrell's Distinguished Career in Alzheimer’s Research

Dr. Ferrell’s illustrious career has witnessed her taking up numerous leadership roles focused on Alzheimer’s research and cognitive health initiatives. Notably, she has contributed to several organizations dedicated to Alzheimer’s causes, including the Davos Alzheimer's Collaborative and the Alzheimer’s Drug Discovery Foundation. Her leadership spans over a decade at Eli Lilly and Company, where she served as the Global Head of External Engagement for Alzheimer’s research.

Dr. Ferrell’s impressive educational background includes a doctorate in Public Health from Indiana University, an MBA from Stanford University, and a Bachelor’s degree in Economics from DePauw University. Her impressive credentials reinforce Circular Genomics' commitment to engaging the best minds in the field to foster groundbreaking advancements in medical science.

Insights from Circular Genomics Leadership

Nikolaos Mellios, the Chief Scientific Officer of Circular Genomics, expressed excitement about Dr. Ferrell’s appointment, stating, “We are thrilled to welcome Dr. Ferrell to our Scientific Advisory Board. Her vast knowledge and experience in Alzheimer's disease research are critical as we continue our quest to find innovative methods for early and accurate diagnosis and treatment.” This enthusiasm underscores the importance of advancing care for conditions like Alzheimer's that impact countless lives each year.

Dr. Ferrell's Perspective on Joining the Team

In her own words, Dr. Ferrell noted, “I am honored to join Circular Genomics' Scientific Advisory Board. The innovative work currently underway in exploring circRNAs as potential biomarkers for Alzheimer's is incredibly promising. With my personal connection to the challenges surrounding brain health, I feel deeply committed to raising awareness and improving treatment options for individuals suffering from Alzheimer’s disease.”

Building a Multi-Disciplinary Team

Dr. Ferrell will collaborate with an already distinguished SAB, which boasts several accomplished specialists in the realms of neurology, psychiatry, and precision medicine. Some prominent members include Roy Perlis, MD from Massachusetts General Hospital, Madhukar Trivedi, MD from UT Southwestern Medical Center, and Carlos Cruchaga, PhD from Washington University School of Medicine, among others. Together, they are poised to impart leading-edge insights that will guide Circular Genomics' research and development strategies.

About Circular Genomics

As a global leader in circular RNA-based precision medicine, Circular Genomics is dedicated to pioneering diagnostic tools and treatment protocols for psychiatric and neurological disorders. Their approach enhances the standard of care by allowing for quicker and more accurate assessments of treatment effectiveness, facilitating tailored patient care based on individual needs. Future products aim to revolutionize patient outcomes within a matter of weeks, ensuring that advancements in brain health are both significant and timely. For more information on their groundbreaking work, visit Circular Genomics.